Findings from the current meta-analysis indicate that pharmacologically inhibiting HDAC6 during the hyperacute phases of AIS confers significant protection, evidenced by smaller infarction sizes and greater recovery of motor function, compared to controls. The gene discussed is HDAC6; the disease is infarction.